FDA-AACR Workshop to Address Multiple Myeloma Clinical Trial Disparities
By Trevan Locke, PhD Thanks to a wave of newly approved therapies in the past two decades, survival rates...
Category: Policy
By Trevan Locke, PhD Thanks to a wave of newly approved therapies in the past two decades, survival rates...
The first new anticancer therapeutics approved by the U.S. Food and Drug Administration (FDA) in 2020 are for the...
The U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called fam-trastuzumab deruxtecan-nxki (Enhertu) for treating...
In the final days of 2019, the U.S. Food and Drug Administration (FDA) expanded the use of a previously...
In 2019, research continued to drive progress across the spectrum of cancer care in the form of new and...
In November and the first half of December, the U.S. Food and Drug Administration (FDA) announced three approvals for...
As 2019 draws to a close, the American Association for Cancer Research (AACR) is grateful for our growing ranks...
Earlier this month, the U.S. Food and Drug Administration (FDA) announced that the Office of Hematology and Oncology Products...
On Wednesday, the U.S. Food and Drug Administration (FDA) expanded the use of the molecularly targeted therapeutic niraparib (Zejula)...
Breast cancer can be a scary diagnosis. Even though mortality rates have declined in recent years in the United...